This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barchiesi, F.
Right arrow Articles by Scalise, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barchiesi, F.
Right arrow Articles by Scalise, G.

 Previous Article

Antimicrobial Agents and Chemotherapy, January 2000, p. 226-229, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens

Francesco Barchiesi,1,* Daniela Arzeni,1 Annette W. Fothergill,2 Luigi Falconi Di Francesco,1 Francesca Caselli,1 Michael G. Rinaldi,2,3 and Giorgio Scalise1

Istituto di Malattie Infettive e Medicina Pubblica, Università degli Studi di Ancona, Ancona, Italy1; Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center, San Antonio, Texas 72284-77502; Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas 78284-51003

Received 7 June 1999/Returned for modification 16 September 1999/Accepted 25 October 1999

A broth microdilution method performed in accordance with the National Committee for Clinical Laboratory Standards guidelines was used to compare the in vitro activity of the new antifungal triazole SCH 56592 (SCH) to that of fluconazole (FLC), itraconazole (ITC), and ketoconazole (KETO) against 257 clinical yeast isolates. They included 220 isolates belonging to 12 different species of Candida, 15 isolates each of Cryptococcus neoformans and Saccharomyces cerevisiae, and seven isolates of Rhodotorula rubra. The MICs of SCH at which 50% (MIC50) and 90% (MIC90) of the isolates were inhibited were 0.06 and 2.0 µg/ml, respectively. In general, SCH was considerably more active than FLC (MIC50 and MIC90 of 1.0 and 64 µg/ml, respectively) and slightly more active than either ITC (MIC50 and MIC90 of 0.25 and 2.0 µg/ml, respectively) and KETO (MIC50 and MIC90 of 0.125 and 4.0 µg/ml, respectively). Our in vitro data suggest that SCH has significant potential for clinical development.

* Corresponding author. Mailing address: Istituto di Malattie Infettive e Medicina Pubblica, Università degli Studi di Ancona, Ospedale Umberto I°, Largo Cappelli 1, 60121, Ancona, Italy. Phone: 39.71.5963467. Fax: 39.71.5963468. E-mail: cmalinf{at}popcsi.unian.it.

Antimicrobial Agents and Chemotherapy, January 2000, p. 226-229, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Parker, J. E., Merkamm, M., Manning, N. J., Pompon, D., Kelly, S. L., Kelly, D. E. (2008). Differential Azole Antifungal Efficacies Contrasted Using a Saccharomyces cerevisiae Strain Humanized for Sterol 14{alpha}-Demethylase at the Homologous Locus. Antimicrob. Agents Chemother. 52: 3597-3603 [Abstract] [Full Text]  
  • Chowdhry, R., Marshall, W. L. (2008). Analytical Reviews: Antifungal Therapies in the Intensive Care Unit. J Intensive Care Med 23: 151-158 [Abstract]  
  • Krishna, G., Sansone-Parsons, A., Martinho, M., Kantesaria, B., Pedicone, L. (2007). Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection. Antimicrob. Agents Chemother. 51: 812-818 [Abstract] [Full Text]  
  • Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M. (2006). In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts.. Antimicrob. Agents Chemother. 50: 2009-2015 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., Rodriguez-Tudela, J. L. (2006). Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi. Antimicrob. Agents Chemother. 50: 917-921 [Abstract] [Full Text]  
  • Pitisuttithum, P., Negroni, R., Graybill, J. R., Bustamante, B., Pappas, P., Chapman, S., Hare, R. S., Hardalo, C. J. (2005). Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56: 745-755 [Abstract] [Full Text]  
  • Serena, C., Fernandez-Torres, B., Pastor, F. J., Trilles, L., Lazera, M. d. S., Nolard, N., Guarro, J. (2005). In Vitro Interactions of Micafungin with Other Antifungal Drugs against Clinical Isolates of Four Species of Cryptococcus. Antimicrob. Agents Chemother. 49: 2994-2996 [Abstract] [Full Text]  
  • Diekema, D. J., Petroelje, B., Messer, S. A., Hollis, R. J., Pfaller, M. A (2005). Activities of Available and Investigational Antifungal Agents against Rhodotorula Species. J. Clin. Microbiol. 43: 476-478 [Abstract] [Full Text]  
  • Zaas, A. K., Boyce, M., Schell, W., Lodge, B. A., Miller, J. L., Perfect, J. R. (2003). Risk of Fungemia Due to Rhodotorula and Antifungal Susceptibility Testing of Rhodotorula Isolates. J. Clin. Microbiol. 41: 5233-5235 [Abstract] [Full Text]  
  • Barchiesi, F., Schimizzi, A. M., Caselli, F., Giannini, D., Camiletti, V., Fileni, B., Giacometti, A., Di Francesco, L. F., Scalise, G. (2001). Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 48: 769-773 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Mills, K., Bolmstrom, A., Jones, R. N. (2001). Evaluation of Etest Method for Determining Posaconazole MICs for 314 Clinical Isolates of Candida Species. J. Clin. Microbiol. 39: 3952-3954 [Abstract] [Full Text]  
  • Barchiesi, F., Arzeni, D., Camiletti, V., Simonetti, O., Cellini, A., Offidani, A. M., Scalise, G. (2001). In Vitro Activity of Posaconazole against Clinical Isolates of Dermatophytes. J. Clin. Microbiol. 39: 4208-4209 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N. (2001). In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans. Antimicrob. Agents Chemother. 45: 2862-2864 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., Walsh, T. J. (2001). Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia. Antimicrob. Agents Chemother. 45: 857-869 [Abstract] [Full Text]  
  • Barchiesi, F., Schimizzi, A. M., Caselli, F., Novelli, A., Fallani, S., Giannini, D., Arzeni, D., Di Cesare, S., Di Francesco, L. F., Fortuna, M., Giacometti, A., Carle, F., Mazzei, T., Scalise, G. (2000). Interactions between Triazoles and Amphotericin B against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44: 2435-2441 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»